DexCom's Asymmetric Setup: A Base Case Funded by Existing Demand, Biggest Catalyst a Free Option

Dexcom is a one-product-category company in the best and most precarious sense: roughly all of its revenue comes from continuous glucose monitors (CGMs) and the disposable sensors that drive their razor-and-blade economics. That concentration is the entire investment debate. The company built CGM into the standard of care for insulin-using diabetics, and the next leg of growth depends on pushing the technology into the far larger population of type 2 diabetics who don't use insulin — a group management pegs at more than 25 million people in the U.S. alone. The bull case is that this expansion is just beginning; the bear case is that it arrives precisely as payers gain the leverage to commoditize CGM pricing. At around $72 a share, well off the $89.98 fifty-two-week high and near the midpoint of its $54.11–$89.98 range, the stock has spent the past year pricing the bear's anxieties. My read is that the sequencing of events over the next several quarters favors the bulls, and that the most-feared negative — Medicare competitive bidding — is a 2028 story the market is over-weighting today.

The clinical unlock the category was missing

For years the obvious objection to CGM in non-insulin type 2 patients was the absence of high-grade randomized evidence that it changes outcomes. That gap closed in early June. At the American Diabetes Association's 2026 Scientific Sessions, Dexcom presented the CONNECT trial, which randomized 283 non-insulin type 2 adults across 21 U.S. primary care practices to a G7 or routine care. Participants using Dexcom G7 achieved an average 1.6% A1C reduction from baseline over 26 weeks — a 0.9% greater reduction than the routine care control group, and at week 26, 68% of CGM users reached an A1C below 7.5% and 46% reached below 7.0%. The effect was largest where it matters most: participants with baseline A1C above 10% saw a 3.1% mean reduction, exceeding controls by more than two percentage points.

Two details make this more than a marketing readout. First, the benefit stacked on top of modern pharmacotherapy rather than substituting for it — glycemic improvements were additive across drug classes, including GLP-1–based therapies and SGLT2 inhibitors. That directly rebuts the lazy thesis that GLP-1s make CGM redundant; in practice they are complements. Second, and more important for the equity, the study's senior author framed it as "the first and only level A evidence demonstrating strong benefit of CGM for the Type 2 non-insulin using population," the highest evidence grade the ADA assigns. Level A evidence has historically driven changes in standards of care — which is the mechanism by which clinical data becomes reimbursement, and reimbursement becomes volume.

Coverage is unlocking now, not in 2028

The market tends to collapse "coverage" into a single binary CMS event and then discount it for timing risk. That misses the commercial channel, which is moving today. Dexcom has already secured coverage for all people with diabetes on the national formularies of the three largest pharmacy benefit managers, an important step toward the 25 million U.S. type 2 patients not on insulin. The next domino is concrete and near-term: management noted that as of this summer Prime Therapeutics will cover Dexcom CGM for all people with diabetes, which sets Dexcom up to have more than 7 million type 2 non-insulin lives covered commercially by the end of 2026.

This is the part of the thesis I think is underappreciated. Commercial wins translate into new patient starts and shifting physician prescribing behavior immediately, without waiting for a federal rulemaking. The Medicare piece is upside layered on top. Dexcom expects CMS to broaden CGM coverage, with broader Medicare coverage potentially allowing nearly 12 million people to access CGMs. CONNECT was explicitly engineered to support that decision, and a CMS proposal this year with implementation around 2027 would roughly double the U.S. covered pool. Crucially, none of this is baked into the numbers: the company's full-year guidance of 11% to 13% revenue growth assumes no benefit from type 2 coverage expansion. That is an asymmetric setup — the base case is funded by existing demand, and the biggest catalyst is a free option.

The product cycle is doing real work on margins

The other reason to be constructive is that the current product transition is simultaneously a growth and a margin event. The G7 15 Day extends wear from 10 to 15.5 days while improving the algorithm and adhesive — the company touts an 8.0% mean absolute relative difference, the most accurate sensor it has cleared — which directly addresses the reliability complaints that dogged the earlier G7 rollout. Management expects roughly half the U.S. base on 15 Day by year-end, with international launches beginning in the back half of 2026. A longer-wear sensor sold at similar reimbursement is structurally accretive to gross margin, and the early numbers show it: first-quarter non-GAAP gross profit reached $757.4 million, or 63.5% of revenue, up from 57.5% a year earlier.

What I find telling is the conservatism around the margin guide. Even after that step-up, management reiterated adjusted gross profit margin guidance of roughly 63–64% while raising adjusted operating margin to 23–23.5% and adjusted EBITDA margin to 31–31.5%. The reason it didn't lift the gross margin band despite tracking ahead is instructive — guidance was left unchanged to account for the current geopolitical environment, including uncertainties with fuel prices and shipping routes. In other words, the resin-and-freight risk is an external macro overhang, not an operational one. If oil and logistics cooperate, the official guardrails look beatable, and the Ireland plant ramp adds a multi-year efficiency lever the sell-side is unlikely to fully credit until it shows up in printed results.

The bear case is real — and deferred

I don't want to wave away the commoditization risk, because it is the correct thing to worry about. The mechanism is specific. CMS has folded CGMs into the DMEPOS competitive bidding program, with contracting beginning in 2027 and payment changes effective in 2028. The design intent is lower pricing: the agency plans to set a single payment amount at the 75th percentile of winning bids rather than the maximum, and to reclassify CGMs as items requiring frequent servicing, phasing in monthly rental payments for receivers. Management's own filing concedes Medicare reimbursement for its systems will decrease beginning in 2028, and that bidding-area pricing tends to pull non-bidding-area prices down with it. Because Medicare rates anchor commercial negotiations, this is a genuine long-term reset of unit economics, not a contained one.

Layer on competition — Abbott's Libre franchise remains aggressive on price, Medtronic is re-engaged with its disposable Simplera sensor, and the FDA's January 2026 broadening of "general wellness device" guidance widens the door for non-traditional entrants — and the structural worry is clear: if broad type 2 CGM becomes price-led, Dexcom's premium positioning has to be earned in measurable outcomes and retention rather than assumed.

But timing matters enormously here, and the bidding cliff simply is not the next-several-quarters story. The 2027 contracting and 2028 payment changes sit beyond the window in which the coverage wins, 15 Day conversion, and margin ramp play out. The right way to hold this stock is to underwrite the near-term catalyst path while watching field-reliability metrics and the competitive bid structure as the medium-term governors on terminal value. Dexcom's defense — a retention advantage management cites as a double-digit-point lead over peers, the longer-wear economics of 15 Day, a tiered portfolio spanning the G-series and ONE+, and a lead in the automated-insulin-delivery ecosystem — is plausible but unproven at scale. CONNECT helps, because durable outcomes and additivity with GLP-1s are exactly the evidence that lets a premium sensor resist becoming a generic.

Quality overhang, now with an activist watching

The thing that genuinely soured sentiment in 2025 was execution, not demand. A March 2025 FDA warning letter citing manufacturing and quality-system non-conformities and a cluster of securities and product class-action suits fed a narrative that operations lagged growth. That overhang is mending rather than resolved, and the catalyst for the repair is notable: Dexcom agreed with activist investor Elliott Investment Management to add two independent directors and revamp a key board committee. Alongside its Investor Day, the company outlined a strategy for durable double-digit growth driven by product innovation, expanded access and operational efficiency, with initiatives including the next-generation G8 platform, expanded Medicare coverage, and multi-analyte sensing. Add the June FDA clearance of an over-the-counter Stelo monitor for children and a reimagined Stelo app, and the product narrative has shifted from defense to offense. The warning-letter resolution remains the single cleanest de-risking event left on the board; until it closes, the quality discount lingers.

Valuation: priced for the worry, not the option

At roughly $72, Dexcom trades near 28x consensus 2026 non-GAAP EPS, easing toward the low-to-mid-20s on 2027 estimates as margins compound — a multiple that, for a company guiding low-double-digit revenue growth with 31%-plus EBITDA margins and a net-cash balance sheet ($2.42 billion in cash and securities at quarter-end against $1.25 billion of convertible notes), is undemanding by the standard of its own history. The street has noticed; price targets clustered in the mid-$80s to mid-$90s after CONNECT, with the high end implying meaningful upside. I don't lean on those targets, but the direction of estimate revisions matters: the incremental news flow — a clean Q1 beat, raised margin guidance, Level A clinical data, an imminent PBM expansion, and a credible path to a CMS proposal — has skewed positive while the multiple still reflects 2025's competitive and quality fears.

Bottom line

The central tension in Dexcom is whether its non-insulin type 2 expansion is a margin-accretive growth wave or a commoditization trap. The resolution is in the sequencing. The catalysts that drive the next several quarters — commercial coverage of all diabetics this summer, G7 15 Day conversion lifting both volume and mix, Ireland efficiencies, and a likely CMS signal supported by the strongest CGM evidence yet generated — all land well before the 2028 DMEPOS reset that the bears fixate on. That reset is real and deserves vigilance, but it does not govern the stock between now and year-end. With governance reinforced by an activist, a net-cash balance sheet, and guidance that gives away the type 2 coverage option for free, I lean constructive, with field-reliability trends and the FDA warning-letter resolution as the metrics that will tell me whether the quality overhang is truly clearing.

Disclaimer: Tenzing Analytics, Inc. is not a registered investment adviser, broker-dealer, or financial institution, and all content provided by Tenzing Memo is AI-generated for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy, sell, or hold any security or financial instrument. Content is general in nature, not tailored to any individual's financial situation or objectives, and may contain errors, omissions, or inaccuracies; it should not be relied upon as a primary basis for any investment decision. Any forward-looking statements are subject to risks and uncertainties and may not reflect actual future results. Users should conduct their own research and consult qualified financial, legal, or tax advisors before making investment decisions, and by accessing this content, you acknowledge and accept these limitations.